Bioxytran, Inc.
BIXT
$0.1567
-$0.0054-3.33%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 454.00K | 295.20K | 609.40K | 756.80K | 465.80K |
| Depreciation & Amortization | 2.90K | 1.50K | 1.50K | 2.00K | 3.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 491.20K | 347.70K | 610.90K | 785.80K | 1.01M |
| Operating Income | -491.20K | -347.70K | -610.90K | -785.80K | -1.01M |
| Income Before Tax | -516.90K | -392.40K | -661.70K | -813.70K | -1.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -516.90K | -392.40K | -661.70K | -813.70K | -1.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.30K | -- | -- | 13.30K | 21.80K |
| Net Income | -503.60K | -392.40K | -661.70K | -800.30K | -1.03M |
| EBIT | -491.20K | -347.70K | -610.90K | -785.80K | -1.01M |
| EBITDA | -488.30K | -346.20K | -609.40K | -783.80K | -1.01M |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 92.93M | 126.39M | 176.61M | 162.81M | 147.57M |
| Average Diluted Shares Outstanding | 92.93M | 126.39M | 176.61M | 162.81M | 147.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |